Terlipressin

CAS No.: 14636-12-5

Terlipressin Chemical Structure

Molecular formula: C₅₂H₇₄N₁₆O₁₅S₂

Molecular weight: 1227. 37 g·mol−1

Patent period: —

Dositive specifications: –

Injection : –

Oral tablets: —

Injection: —

Get in touch Download

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Biological Activity

Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells.

Chemical Properties

CAS NO.	14636-12-5
FORMULA	C₅₂H₇₄N₁₆O₁₅S₂
M. WT	1227. 37
PURITY	—
SMILES	O=C ([C@H] (CSSC[C@@H] (C (N[C@H] (C1=O) CC2=CC=C (O) C=C2) =O) NC (CNC (CNC (CN) =O) =O) =O) NC ([C@@H] (NC ([C@@H] (NC ([C@] (N1) ([H]) CC3=CC=CC=C3) =O) CCC (N) =O) =O) CC (N) =O) =O) N (CCC4) [C@@H]4C (N[C@@H] (CCCCN) C (NCC (N) =O) =O) =O
STORAGE	Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Online Inquiry

Other Drug Peptide More+

Linaclotide new

Linaclotide is a potent and selective guanylate cyclase C agonist; Developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.
Thymalfasin

Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.
Atosiban

Atosiban is a peptide Oxytocin Receptor Inhibitor. Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra) . Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells and reduced influx of Ca2+ from the extracellular space through voltage-gated channels occur. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.
Tesamorelin

EGRIFTA is a growth hormone releasing factor (GRF) analogindicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy:

Product Catalog